Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Clinical value of flow cytometric immunophenotypic analysis for minimal residual disease detection in autologous stem-cell products of follicular and mantle cell lymphomas

Leukemia volume 26, pages 166–169 (2012)Cite this article

A Corrigendum to this article was published on 07 August 2013

Graft purging can translate into more durable disease remission in patients with follicular lymphoma (FL) and mantle cell lymphoma (MCL). Currently, polymerase chain reaction (PCR) is the most widely used technique for assessment of minimal residual disease (MRD) during and after treatment. However, maximally 40–60% of the t(11;14) breakpoints or clonal immunoglobulin rearrangement in MCL can be detected using consensus PCR primers,1, 2 and there is no worldwide standard protocol to evaluate MRD in hematopoietic stem-cell products. For exploration of a broadly sensitive assay, we conducted a retrospective study to evaluate usefulness and clinical value of flow cytometric immunophenotyping (FCM) to detect MRD in stem-cell products of FL and MCL.

Subjects were 30 patients (19 FL and 11 MCL) undergoing autologous stem-cell transplantation (ASCT) in our institute. Patient characteristics were given in Table 1. They were diagnosed as advanced stage diseases with bone marrow/peripheral blood involvement. All patients had available FCM data before pretransplant induction chemotherapy and of stem-cell grafts.

Table 1 Patients’ characteristics (n=30)
Full size table

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17: 2257–2317.

    Article  CAS  Google Scholar 

  2. Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008; 112: 2687–2693.

    Article  CAS  Google Scholar 

  3. Kato H, Taji H, Ogura M, Kagami Y, Oki Y, Tsujimura A et al. Favorable consolidative effect of high-dose melphalan and total-body irradiation followed by autologous peripheral blood stem cell transplantation after rituximab-containing induction chemotherapy with in vivo purging in relapsed or refractory follicular lymphoma. Clin Lymphoma & Myeloma 2009; 9: 443–448.

    Article  CAS  Google Scholar 

  4. Andersen NS, Donovan JW, Borus JS, Poor CM, Neuberg D, Aster JC et al. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood 1997; 90: 4212–4221.

    CAS  Google Scholar 

  5. Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnson HE et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003; 21: 3918–3927.

    Article  CAS  Google Scholar 

  6. Corradini P, Ladetto M, Zallio F, Astolfi M, Rizzo E, Sametti S et al. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol 2004; 22: 1460–1468.

    Article  Google Scholar 

  7. Bottcher S, Ritgen M, Buske S, Gesk S, Klapper W, Hoster E et al. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations. Haematologica 2008; 93: 551–559.

    Article  Google Scholar 

  8. Sanchez ML, Almeida J, Vidriales B, Lopez-Berges MC, Garcia-Marcos MA, Moro MJ et al. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation. Leukemia 2002; 16: 1460–1469.

    Article  CAS  Google Scholar 

  9. Oki Y, Ogura M, Kato H, Kikuchi A, Taji H, Kagami Y et al. Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Cancer Sci 2008; 99: 179–184.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank all the doctors and nurses for their excellent patients’ care. We would also like to say special thanks to Koichi Koike, Hiroshi Hamashima, Yasutaka Okada, Junko Ozeki and Mako Hagino for their excellent laboratory works. This study was supported partially by Grant-in-Aid for Scientific Research (KAKENHI); Health and Labor Science Research Grant.

Author information

Authors and Affiliations

  1. Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan

    H Kato, K Yamamoto, Y Oki, S Ine, H Taji, D Chihara, Y Kagami & Y Morishima

  2. Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan

    H Kato & M Seto

Authors
  1. H Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y Oki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Ine
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H Taji
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D Chihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Y Kagami
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M Seto
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Y Morishima
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y Morishima.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kato, H., Yamamoto, K., Oki, Y. et al. Clinical value of flow cytometric immunophenotypic analysis for minimal residual disease detection in autologous stem-cell products of follicular and mantle cell lymphomas. Leukemia 26, 166–169 (2012). https://doi.org/10.1038/leu.2011.183

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2011.183

This article is cited by

Search

Advanced search

Quick links